AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program
Rhea-AI Summary
AEON (NYSE American: AEON) reported full-year 2025 results and updates on its ABP-450 biosimilar program. Key highlights: analytical data showed 100% amino-acid sequence match to BOTOX® with 93–99% sequence coverage, constructive FDA BPD Type 2a feedback, a $6.0M PIPE plus note exchange reducing debt >90%, and a new CFO appointment.
Cash was $3.0M at year-end 2025; including $4.2M PIPE proceeds, liquidity is expected to fund operations into Q3 2026.
Positive
- Analytical comparability: 100% amino-acid sequence match to BOTOX across >3,400 residues
- FDA feedback: BPD Type 2a meeting gave a clear analytical framework for 351(k) pathway
- Balance sheet: $6.0M PIPE financing plus note exchange reduced outstanding debt by >90%
- Liquidity extension: $4.2M second PIPE closing improves cash runway into Q3 2026
- Leadership: Appointment of John Bencich as CFO with 25+ years of capital markets experience
Negative
- Low cash balance: $3.0M cash at December 31, 2025 before $4.2M PIPE proceeds
- Short runway: Liquidity only expected to fund operations into Q3 2026, implying near-term financing need
News Market Reaction – AEON
In the Mar 31 session, AEON declined 0.45%, reflecting a mild negative market reaction. Argus tracked a trough of -10.1% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 14 | Q3 2025 earnings | Positive | -3.8% | Q3 2025 update with LC-MS biosimilarity data and $6M PIPE financing. |
| May 14 | Q1 2025 earnings | Positive | -1.0% | Q1 2025 results, 351(k) biosimilar strategy, and $10.4M cash update. |
| Mar 24 | FY 2024 earnings | Positive | -7.3% | FY 2024 results with ABP-450 progress and $20M equity financing. |
| Nov 13 | Q3 2024 earnings | Positive | -11.3% | Q3 2024 results and biosimilar advisory meeting outlining 351(k) path. |
| Aug 12 | Q2 2024 earnings | Positive | -1.0% | Q2 2024 update on ABP-450 biosimilar plans and pivotal CD study design. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings and financial updates have historically been followed by negative price moves despite constructive biosimilar and funding narratives.
Over recent earnings cycles, AEON has repeatedly paired financial results with ABP-450 biosimilar progress and financing steps. Updates from Q2 2024 through Q3 2025 highlighted the 351(k) pathway, initiation of analytical studies, positive LC-MS biosimilarity data, and capital raises, including a $6 million PIPE. Yet 24-hour moves after these earnings releases were often negative, even with improvements in cash runway and regulatory positioning. Today’s full-year 2025 results and positive FDA feedback fit this pattern of strategic advancement alongside funding concerns.
Key Terms
biosimilar medical
351(k) biosimilar pathway regulatory
liquid chromatography/mass spectrometry (lc/ms) medical
ld50 medical
elisa medical
snap-25 medical
pipe financing financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
– Announced positive initial comparative analytical results, confirming identical amino-acid sequencing and highly similar functional characteristics to BOTOX® –
– Reported positive FDA BPD Type 2a meeting, with FDA feedback providing a clear framework for advancing the comparative analytical plan for ABP-450 biosimilar program –
– Strengthened balance sheet through
– Appointed John Bencich as Chief Financial Officer, adding significant capital markets and strategic leadership experience –
IRVINE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve full-label U.S. market entry, today announced its financial results for the full year ended December 31, 2025, and provided a business update.
“We’ve advanced the ABP-450 program with a positive FDA meeting and supportive initial comparative analytical results that reinforce our biosimilar development strategy,” said Robert Bancroft, President and Chief Executive Officer of AEON. “The Agency’s feedback supports AEON’s proposed framework for completing our analytical program and preparing for our next regulatory interaction. At the same time, we strengthened our balance sheet through our recent financing and note exchange, positioning the Company to execute this next stage of development. With strong foundational biosimilarity data in hand, we are entering the next development phase with greater scientific, regulatory, and financial clarity, and remain confident in our strategy to pursue full-label U.S. market entry for ABP-450.”
Recent Clinical and Corporate Highlights
- Positive Biosimilarity Results
- In November 2025, AEON reported positive initial comparative data for ABP-450, its proposed biosimilar to BOTOX®. These initial analytical results confirmed identical amino-acid sequencing and highly similar functional characteristics to BOTOX®. These analytical results were included in the package submitted to the FDA ahead of AEON’s BPD Type 2a meeting.
- Liquid chromatography/mass spectrometry (LC/MS) analysis of over 3,400 amino acids demonstrated that the primary structure of ABP-450 exhibited a
100% sequence match to BOTOX®, based on sequence coverage of 93–99% across all five proteins comprising the 900 kDa botulinum toxin type A complex. - Functional analyses demonstrated initial similarity in potency (using LD50 and cell-based potency assays), composition (vial-to-vial comparability analyzed with ELISA), and enzymatic activity (functional cleavage of SNAP-25 consistent with mechanism of action).
- Liquid chromatography/mass spectrometry (LC/MS) analysis of over 3,400 amino acids demonstrated that the primary structure of ABP-450 exhibited a
- The Company continues to build on this analytical biosimilarity foundation and expects the majority of its analytical comparability program to be completed in 2026.
- In November 2025, AEON reported positive initial comparative data for ABP-450, its proposed biosimilar to BOTOX®. These initial analytical results confirmed identical amino-acid sequencing and highly similar functional characteristics to BOTOX®. These analytical results were included in the package submitted to the FDA ahead of AEON’s BPD Type 2a meeting.
- Announced Constructive FDA Feedback Following January 2026 Biosimilar Biological Product Development (BPD) Type 2a Meeting
- AEON reported that the U.S. Food and Drug Administration (“FDA” or the “Agency”) reviewed the Company’s proposed analytical similarity strategy under the 351(k) biosimilar pathway and noted that AEON’s analytical methodologies appeared reasonable to support advancement of the program toward a comprehensive analytical similarity package. The Company believes the FDA’s feedback provides a clear framework for the remaining analytical components of its biosimilar development program and plans to complete the majority of its analytical comparability program in 2026.
- AEON currently plans to request a BPD Type 2b meeting in 2026 to discuss the next phase of the development program to support approval of ABP-450 as a biosimilar to BOTOX® across all approved therapeutic indications.
- Strategic PIPE Financing and Note Exchange
- AEON announced complementary transactions through a
$6 million PIPE financing and a Daewoong Pharmaceutical note exchange – which, together, strengthens AEON’s balance sheet and reduces outstanding debt by more than90% .
- AEON announced complementary transactions through a
- Appointed John Bencich as Chief Financial Officer
- In March 2026, the Company announced the appointment of John Bencich as Chief Financial Officer. Mr. Bencich joins AEON with more than 25 years of leadership experience spanning corporate strategy, capital market transactions, and business development across emerging growth and publicly traded companies.
- Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual Meeting
- Also in March 2026, AEON announced a poster presentation at the 2026 American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22, 2026, in Chicago, IL, titled Establishing Primary Structure Comparability Between ABP-450 (prabotulinumtoxinA) and OnabotulinumtoxinA (BOTOX®) to Support Biosimilarity.
- Also in March 2026, AEON announced a poster presentation at the 2026 American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22, 2026, in Chicago, IL, titled Establishing Primary Structure Comparability Between ABP-450 (prabotulinumtoxinA) and OnabotulinumtoxinA (BOTOX®) to Support Biosimilarity.
Liquidity and Capital Resources
- The Company reported cash and cash equivalents of
$3.0 million as of December 31, 2025, which does not include the$4.2 million of proceeds received upon the second closing of the PIPE financing in January 2026. Including those proceeds, cash and cash equivalents are expected to be sufficient to fund the Company’s operating plan into the third quarter of 2026.
About the U.S. Biosimilar Pathway
Analytical similarity forms the scientific foundation of the 351(k) pathway and represents the most data-intensive phase of biosimilar development. When analytical comparability across critical quality attributes is robustly demonstrated, the FDA may reduce the scope of required clinical studies under its totality-of-the-evidence framework. Sponsors may also seek extrapolation to additional indications of the reference product when scientifically justified.
About AEON Biopharma
AEON Biopharma is a biopharmaceutical company seeking full-label access to the U.S. therapeutic neurotoxin market via biosimilarity to BOTOX®. The U.S. therapeutic neurotoxin market exceeds
Forward-Looking Statements
Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or AEON’s future financial or operating performance. For example, statements regarding meetings with the FDA, the timing of completion of, or outcome of results from, primary comparative analytical studies, or potential determination that ABP-450 is highly similar to the reference product for currently approved and future therapeutic indications are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "plan", "possible", "forecast", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements.
These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by AEON and its management, are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) the completion of additional analytical testing of ABP-450; (ii) the completion of additional functional analyses of ABP-450; (iii) the expected Type 2b meeting with the FDA and potential path forward to biosimilarity designation; (iv) AEON’s ability to receive full-label access to the U.S. therapeutic neurotoxin market via biosimilarity to BOTOX® on an accelerated timeline or at all; (v) the outcome of any legal proceedings that may be instituted against AEON or others; (vi) AEON’s future capital requirements; (vii) AEON’s ability to raise financing in the future; (viii) AEON’s ability to continue to meet continued stock exchange listing standards; (ix) the possibility that AEON may be adversely affected by other economic, business, regulatory, and/or competitive factors; (x) the outcomes from any meetings or discussions with regulatory authorities; (xi) the timing of, or results from, any testing performed on AEON’s product; and (xii) other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s filings with the Securities and Exchange Commission (the "SEC"), which are available on the SEC’s website at www.sec.gov.
Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. AEON does not undertake any duty to update these forward-looking statements.
Contacts
Investor Contact:
Laurence Watts
New Street Investor Relations
+1 619 916 7620
laurence@newstreetir.com
Source: AEON Biopharma
| AEON BIOPHARMA, INC. CONSOLIDATED BALANCE SHEETS (in thousands, except share data and par value amounts) | ||||||||
| December 31, | December 31, | |||||||
| 2025 | 2024 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 3,006 | $ | 13 | ||||
| Prepaid expenses and other current assets | 392 | 1,577 | ||||||
| Total current assets | 3,398 | 1,590 | ||||||
| Property and equipment, net | 162 | 235 | ||||||
| Operating lease right-of-use asset | 1,052 | 1,288 | ||||||
| Other assets | 948 | 29 | ||||||
| Total assets | $ | 5,560 | $ | 3,142 | ||||
| LIABILITIES AND STOCKHOLDERS' DEFICIT | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 942 | $ | 5,910 | ||||
| Accrued clinical trials expenses | 1,426 | 3,571 | ||||||
| Accrued compensation | 2,872 | 1,068 | ||||||
| Other accrued expenses | 1,657 | 3,600 | ||||||
| Total current liabilities | 6,897 | 14,149 | ||||||
| Convertible notes at fair value, including related party amount of | 34,600 | 11,689 | ||||||
| Operating lease liability | 893 | 1,145 | ||||||
| Derivative liability | 14,879 | — | ||||||
| Warrant liabilities | 3,276 | 1,187 | ||||||
| Contingent consideration liability | 42 | 3,541 | ||||||
| Total liabilities | 60,587 | 31,711 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ Deficit: | ||||||||
| Class A common stock, | 9 | 4 | ||||||
| Additional paid-in capital | 415,783 | 403,024 | ||||||
| Accumulated deficit | (470,819 | ) | (431,597 | ) | ||||
| Total stockholders' deficit | (55,027 | ) | (28,569 | ) | ||||
| Total liabilities and stockholders' deficit | $ | 5,560 | $ | 3,142 | ||||
| AEON BIOPHARMA, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME (in thousands, except share and per share data) | ||||||||
| Years Ended December 31, | ||||||||
| 2025 | 2024 | |||||||
| Operating expenses: | ||||||||
| Selling, general and administrative | $ | 12,208 | $ | 13,643 | ||||
| Research and development | 4,094 | 14,181 | ||||||
| Change in fair value of contingent consideration | (3,499 | ) | (100,809 | ) | ||||
| Total operating costs and expenses | 12,803 | (72,985 | ) | |||||
| (Loss) income from operations | (12,803 | ) | 72,985 | |||||
| Other (loss) income: | ||||||||
| Change in fair value of convertible notes | (22,911 | ) | 3,311 | |||||
| Change in fair value of warrants | 84,934 | (14,719 | ) | |||||
| Loss on issuance of warrants | (75,644 | ) | — | |||||
| Loss on embedded forward purchase agreements | — | (19,667 | ) | |||||
| Loss on derivative liability | (13,088 | ) | — | |||||
| Other income, net | 290 | 95 | ||||||
| Total other loss, net | (26,419 | ) | (30,980 | ) | ||||
| (Loss) income before taxes | (39,222 | ) | 42,005 | |||||
| Income taxes | — | — | ||||||
| Net (loss) income | $ | (39,222 | ) | $ | 42,005 | |||
| Basic net (loss) income per share | $ | (3.95 | ) | $ | 77.74 | |||
| Diluted net (loss) income per share | (3.95 | ) | 72.93 | |||||
| Weighted average shares of common stock outstanding used to compute basic net (loss) income per share | 9,921,587 | 540,360 | ||||||
| Weighted average shares of common stock outstanding used to compute diluted net (loss) income per share | 9,921,587 | 575,945 | ||||||
The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). The consolidated financial statements include the accounts of the Company and its controlled subsidiaries.
